Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Pharvaris ( (PHVS) ) is now available.
On April 2, 2026, Pharvaris reported fourth-quarter and full-year 2025 results that underline its transition toward late-stage commercialization in rare angioedema disorders. The company closed 2025 with €291.7 million in cash and cash equivalents, increased R&D spend of €124.5 million, and a full-year net loss of €175.7 million as it advanced multiple pivotal trials, signaling a deliberate investment push ahead of potential product launches.
Operationally, Pharvaris completed enrollment in CHAPTER-3, its pivotal Phase 3 trial of deucrictibant extended-release for prophylactic treatment of hereditary angioedema attacks, with topline data expected in the third quarter of 2026. It also remains on track to submit a U.S. NDA in the first half of 2026 for deucrictibant immediate-release capsules for on-demand HAE treatment, while continuing enrollment in CHAPTER-4 and the CREAATE Phase 3 program targeting acquired angioedema due to C1 inhibitor deficiency.
Management highlighted the positive late-2025 Phase 3 RAPIDe-3 readout, in which deucrictibant showed rapid onset and complete symptom resolution times versus placebo, reinforcing its potentially differentiated oral profile in on-demand HAE care. These clinical achievements, combined with a solid liquidity position and upcoming investor conference appearances in May 2026, position Pharvaris as an increasingly prominent competitor in the rare-disease angioedema market and a company approaching key regulatory and clinical inflection points.
The most recent analyst rating on (PHVS) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.
The score reflects high fundamental risk from being pre-revenue with widening losses and heavy negative free cash flow, partly offset by a low-debt balance sheet and solid equity base. Technically, price action is supportive (trading above key moving averages with neutral-to-positive momentum), while valuation is constrained by negative earnings and no dividend data.
To see Spark’s full report on PHVS stock, click here.
More about Pharvaris
Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists for bradykinin-mediated conditions, including hereditary and acquired angioedema. Its lead candidate, deucrictibant, is being advanced in immediate-release and extended-release formulations to offer injectable-like efficacy with the convenience of oral administration for both on-demand and prophylactic treatment of angioedema attacks.
The company targets unmet needs across all types of bradykinin-mediated angioedema, aiming to establish a new standard of care through sustained efficacy, rapid symptom relief, and a well-tolerated safety profile. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsules for on-demand HAE treatment while running global Phase 3 programs for prophylaxis in HAE and both prophylactic and on-demand treatment in AAE-C1INH.
Average Trading Volume: 166,741
Technical Sentiment Signal: Buy
Current Market Cap: $1.89B
For detailed information about PHVS stock, go to TipRanks’ Stock Analysis page.